Emerging therapies for CNS tumours: key clinical trial updates to watch at ASCO 2026
At the 2026 American Society of Clinical Oncology (ASCO) annual congress, oral abstract presenters highlighted new and exciting central nervous …
Post
-
-
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture
Legend Biotech presented preliminary results from its ongoing Phase I/II trial of LB2102 (NCT05680922), an armoured delta-like ligand 3 (DLL3)-targeted …
-
ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC
At the 2026 American Society of Clinical Oncology (ASCO) annual congress, Pfizer presented top line data for the Phase III …
-
Smart pharma is no longer a buzzword: pharma technological breakthroughs at PHARMAP 2026
In recent years, the context surrounding the pharmaceutical industry has been growing towards digitalisation of processes. Manual operations in pharma …
-
BMS secures FDA acceptance for Camzyos sNDA
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos …
-
ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC
At the 2026 American Society of Clinical Oncology (ASCO) annual congress, Pfizer presented top line data for the Phase III …
-
Smart pharma is no longer a buzzword: pharma technological breakthroughs at PHARMAP 2026
In recent years, the context surrounding the pharmaceutical industry has been growing towards digitalisation of processes. Manual operations in pharma …
-
BMS secures FDA acceptance for Camzyos sNDA
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos …
-
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn. The …
-
ATS 2026: Insmed shines in bronchiectasis with spotlight on Brinsupri
At the 2026 American Thoracic Society (ATS) international conference, Insmed’s presence featured a strong focus on Brinsupri (brensocatib), the first-to-market …
-
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
At the 2026 American Society of Clinical Oncology (ASCO) annual congress, topline data from the Phase III RASolute 302 was …
-
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease
Platinum-sensitive ovarian cancer (PSOC) remains difficult to treat despite its responsiveness to mainstay platinum-based chemotherapies, as cumulative toxicities and diminishing …
-
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
During the American Society of Clinical Oncology (ASCO) meeting 2026, data were presented for a number of cancer vaccines, including …
-
ASCO26: key readouts in lung cancer
As professionals from across the oncology landscape gather at the 2026 American Society of Clinical Oncology (ASCO) congress in Chicago, …
-
ASCO26: BMS and J&J debut shining multiple myeloma data
Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data …
